clinical trial · NCT01420523
Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy
ANRS, Emerging Infectious Diseases·phase2·terminated·n = 48
Human Immunodeficiency VirusLipohypertrophyRaltegravir-Maraviroc
brief summary
Evaluation of antiretroviral therapy combining Raltegravir and Maraviroc in patients with virological success, presenting with clinical lipohypertrophy.
started
Dec 1, 2011
primary completion
Apr 1, 2013
completion
Apr 1, 2013
last updated
Apr 2, 2026
detailed description
Assess the ability to maintain the plasma HIV viral load below the threshold needed for detection (\< 50 copies/mL) at 24 weeks of raltegravir/maraviroc therapy without NRTIs and PIs, in patients with virological success and presenting with clinical lipohypertrophy.
official title
Phase II Pilot Study Evaluating the Efficacy of Dual Therapy With Raltegravir Plus Maraviroc in Patients Receiving Suppressive Antiretroviral Therapy and Presenting With Lipohypertrophy (ANRS 157 ROCnRAL).
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol